COVID19 impact on the API manufacturing companies
Loading player...
Investec India hosted Mr. Mahesh P, Promoter - Viruj Pharmaceuticals for a discussion on the COVID19 impact on the API manufacturing companies.
Mr Mahesh said that India has the capabilities to manufacture APIs in India adding that post the COVID19, many countries are planning on shifting their base from China to our geographies which include India.
Mr. Mahesh is the promoter and managing director of Viruj Pharmaceuticals (an Hyderabad based API manufacturing company). Mr Mahesh has been a part of the pharma industry for 25+ years now and prior to setting up Viruj Pharmaceuticals (2014), he worked extensively with pharma cos such as Glenmark and Neuland at senior management positions.
Mr Mahesh said that India has the capabilities to manufacture APIs in India adding that post the COVID19, many countries are planning on shifting their base from China to our geographies which include India.
Mr. Mahesh is the promoter and managing director of Viruj Pharmaceuticals (an Hyderabad based API manufacturing company). Mr Mahesh has been a part of the pharma industry for 25+ years now and prior to setting up Viruj Pharmaceuticals (2014), he worked extensively with pharma cos such as Glenmark and Neuland at senior management positions.
